Drug Evaluations: Drug Evaluation Central & Peripheral Nervous Systems: ‘Seroquel’ (quetiapine): Preclinical and clinical findings of a new atypical antipsychotic

References to Primarv Literature

• KANE JM. Treatment of schizophrenia. Schizophr. Bull. (1987) 13:133–156.
   PubMed Web of Science ®Google Scholar
• KANE JM, HONIGFELD G, SINGER J, MELTZER HY: Clozap-Inc for the treatment-resistant schizophrenic a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry (1988) 45:789–796.
   PubMed Web of Science ®Google Scholar
• TARSEY D: Neuroleptic-induced extrapyramidal reac-tions: classification, description, and diagnosis. Chi. Neuropharmacol. (1983) 6\(Suppl. 1):S9–S26.
   Google Scholar
• BALDESSARINI RJ, COLE JO, DAVIS JM: Tardive dyskine-sia: summary of a task force report of the American Psychiatric Association. Am.J.Psychiatry(1980) 137:1163–1172.
   PubMed Web of Science ®Google Scholar
• HAMNER MB, ARVANMS LA, MILLER BG, LINK CGG,HONG WW: Plasma prolactin in schizophrenic subjects treated with Seroquel (quetiapine). Psychopharmacol. Bull. (1996) 32:107–110.
   PubMed Web of Science ®Google Scholar
• CASEY DE: Clozapine: neuroleptic-induced EPS andtardive dys kines la. Psychopharmacology (1989) 33:847–S53.
   Google Scholar
• FITTON A, HEEL RC: Clozapine. A review of its pharma-cological properties, and therapeutic use in schizophre-nia. Drugs (1990) 40:722–747.
   Google Scholar
• GROHMANN R, RHTHER E, SASSIM N, SCHMIDT LG: Adverse effects of clozapine. Psychopharmacology (1989) 99:101–104.
   PubMed Web of Science ®Google Scholar
• ALVIR pi, LIEBERMAN JA, SAFFERMAN AZ, SCHWIMMERJL, SCHAAF JA: Clozapine-induced agranulocytosis. Inci-dence and risk factors in the United States. New Engl. J. Med. (1993) 329:162–167.
   PubMed Web of Science ®Google Scholar
• TOTH P, FRANKENBURG FR: Clozapine and seizures: a review. Can]. Psychiatry (1994) 39:236–238.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JM: Preclinical tests that predict clozapine-like atypical antipsychotic actions. In: Critical Issues inthe Treatment of Schizophrenia. Karger, Basel, Switzerland (1995) 10:95–101.
   Google Scholar
• GOLDSTEIN JM: Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp. Opin. Invest. Drugs (1995) 4:291–298.
   Google Scholar
• SAUER CF, SALAMA AL: Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (1993) 112:285–292.
   Google Scholar
• GOLDSTEIN JM, SNYDER DH: Effects of Seroquel, clozap-ine, and other putative atypical antipsychotic agents in primate models of dystonia [Abstract]. Schizophr. Res. (1995) 15:152.
   Web of Science ®Google Scholar
• GOLDSTEIN JM, LITWIN LC, SUTTON EB, MALICK JB:Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology (1993) 112:293–298.
   PubMed Web of Science ®Google Scholar
• MIGLER BM, WARAWA EJ, MALICK JB: Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology (1993) 112:299–307.
   Google Scholar
• ELLENBROEK BA, WILLEMEN A, COOLS AR: Are antago-nists of the dopamine Di receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study inJava monkeys. Neuropsychopharmacology (1991) 2:191–199.
   Web of Science ®Google Scholar
• MORSE JL, EWING Bj, ZULESKI FR et al.: The dispositionand metabolism of Seroquel (ICI 204,636) in rat, dog, monkey and man. 4th International ISSX Meeting. Seattle, WA (August 27–31, 1995).
   Google Scholar
• WONG YW, EWING BJ, FABRE LF, THYRUM PT, YEH C:Multiple dose pharmacokinetics and dose proportion-ality study of SEROQUEL (ICI 204,636) in male schizo-phrenic patients. 34th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico (1995).
   Google Scholar
• WONG YW, EWING BJ, JASKIW G, THYRUM PT, YEH C:Multiple-doses of 'Seroquel' (quetiapine) in elderly psy-chotic patients. 149th Annual Meeting of the American Psychiatric Association. New York, New York (May 4–9, 1996).
   Google Scholar
• WONG YW, EWING BJ, THYRUM PT, YEH C, MARBURYTC: Pharmacokinetics of 'Seroquel' (quetiapine) in hepatic and renal insufficiency. X World Psychiatric Association Meeting. Madrid, Spain (August 23–28, 1996).
   Google Scholar
• ACADEMIC HIGHLIGHTS: Seroquel: a putative atypicalantipsychotic drug with serotonin- and dopatnine-re-ceptor antagonist properties. Preclinical and early clinical trials in schizophrenia.]. din. Psychiatry (1995) 56:438–445.
   Google Scholar
• HIRSCH SR, LINK CGG, GOLDSTEIN JM, ARVANITIS LA: ICI 204,636: a new atypical antipsychotic drug. Br. J. Psy-chiatry (1996) 168\(Suppl. 29):46–58.
   Google Scholar
• FABRE LF, ARVANITIS L, PULTZ J et al.: la 204,636, a ccnovel, atypical antipsychotic: early indication of safetyand efficacy in patients with chronic and subchronic schizophrenia. Clin. 7ber. (1995) 17:366–378.
   Google Scholar
• MELTZER HY, HIRSCH SR, ARVANITIS LA, MB LER BG, AND THE INTERNATIONAL SEROQUEL STUDY GROUP: Quetiapine, an atypical antipsychotic an open-label international multicenter trial of efficacy and safety in patients with acute psychotic symptoms. Submitted.
   Google Scholar
• BORISON RL, ARVANITIS LA, MILLER BG, AND THE US SEROQUEL STUDY GROUP: ICI 204,636, an atypical an-tipsychotic: efficacy and safety in a multicenter, pla-cebo-controlled trial in patients with schizophrenia. J. Clin. Psychopharmacol. (1996) 16:158–169.
   Google Scholar
• SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK esCGG, AND THE SEROQUEL STUDY GROUP: The efficacyand safety of 'Seroquel' (quetiapine) in patients with schizophrenia: a high- and low-dose, double-blind com-parison with placebo. Submitted.
   Google Scholar
• HIRSCH S, ARVANITIS L, MILLER B, SMITH A, SEROQUEL STUDY GROUP: A multicentre, double-blind, placebo-controlled comparison of low and high dosage regi-mens of 'Seroquel' in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schi7ophrenia. 7th Congress of the European College of Neuropsychopharmacology. Jerusalem (1994).
   Google Scholar
• PEUSKENS J, LINK CGG: A comparison of ICI 204,636 and chlorpromazine in the treatment of schizophrenia.Submitted.
   Google Scholar
• LINK C, SMITH A, MILLER B, RYAN J, AND THE SEROQUELSTUDY GROUP: A multicentre, double-blind controlled comparison of Seroquel and chlorpromazine in the treatment of hospitalised patients with acute exacerba-tion of subchronic and chronic schizophrenia [Ab-stract]. Eur. Neuropsychopharmacol. (1994) 4(3, Special Issue):385.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (3rd Edition, revised). American Psychiatric Association, Washington DC (1987).
   Google Scholar
• OVERALL JE, GORHAM DR: Brief Psychiatric Rating Scale. Psychol. Rep. (1962) 10:799–812.
   Web of Science ®Google Scholar
• CGI, Clinical Global Impression. In: ECDEU Assessment Manual for Psychopharmacology (Revised Edition). Guy W (Ed.), United States Department of Health, Education, and Welfare, Rockville, MD (1976):218–222.
   Google Scholar
• BALDESSARINI RJ, COHEN BM, TEICHER MH: Significance of neuroleptic dose and plasma level in the pharma-cologic treatment of psychoses. Arch. Gen. Psychiatry (1988) 45:79–91.
   PubMed Web of Science ®Google Scholar
• ANDREASEN N: Modified scale for the assessment of negative symptoms. NIMH treatment strategies in schizophrenia study. In: Public Health Administration. Department of Health and Human Services (1984).
   Google Scholar
• KAY SR, OPLER LA, LINDENMAYER J-P: The Positive and Negative Syndrome Scale (PANSS): rationale and stand-ardisation. Br. J. Psychiatry (1989) 155:59–65.
   Google Scholar
• SIMPSON GM, ANGUS JWS: A rating scale for extra-pyramidal side-effects. Acta Psychiatr. Scand. (1970) 45(Suppl 212):11–19.
   Google Scholar
• BARNES THE: A rating scale for drug-induced akathisia. Br. J. Psychiatry (1989) 154:672–676.
   PubMed Web of Science ®Google Scholar
• AIMS: Abnormal Involuntary Movement Scale. In: EC-DEU Assessment Manual for Psychopharmacology (Revised Edition). Guy W (Ed.), US Department of Health, Education, and Welfare, Rockville, MD (1976):534–535.
   Google Scholar
• KING DJ, LINK CGG, KOWALCYK B: A multicenter, double-blind, randomized comparison of two dose regi-mens of ICI 204,636 in the treatment of subjects with acute exacerbations of subchronic or chronic schizo-phrenia. Manuscript in preparation.
   Google Scholar
• ARVANITIS LA, MILLER BG: A North American, multiple fixed-dose trial of `Seroquel' (quetiapine) in patientswith acute exacerbation of chronic schizophrenia. Manuscript in preparation.
   Google Scholar
• FLEISCHBACKER WW, LINK CG: A multicenter, double-blind, randomized comparison of dose and dose regi-men of Seroquer in the treatment of patients with schizophrenia. 34th Annual Meeting of the American Col-lege of Neuropsychopharrnacology. San Juan, Puerto Rico (1995).
   Google Scholar
• ARVANITIS IA: Seroquel (ICI 204,636), a new 'atypical' antipsychotic overview of clinical development. 34th Annual Meeting of the American College of Neuropsychophar-macology. San Juan, Puerto Rico (1995).
   Google Scholar
• HONG WW, ARVANITIS LA: The atypical profile of Sero-quel (ICI 204,636) is supported by the lack of sustained elevation of plasma prolactin in schizophrenic pa-tients. 34th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico (1995).
   Google Scholar
• COHEN S, CHILES J, MACNAUGHTON A: Weight gain associated with clozapine. Am. J. Psychiatry (1990) 147:503–504.
   PubMed Web of Science ®Google Scholar